New Imaging Compound Might Help Identify Alzheimer’s Disease Earlier
While research has yet to find a promising treatment or cure for Alzheimer’s disease, doctors are now looking at early intervention before symptoms even appear. A recent study, published in Scientific Reports, is looking at identifying signs of Alzheimer’s before it does permanent damage.
For most cases of Alzheimer’s, symptoms do not appear until up to 10 years after the start of subtle changes in the brain. This stage is known as the preclinical stage, and learning more about this stage could be the key to unlocking more preventative treatments.
Using positron emission tomography (PET) scans, researchers from Washington University School of Medicine looked at the brains of seemingly healthy patients.
Before the scan, the researchers gave patients Fluselenamyl, a new compound used to detect amyloid beta protein plaques. These plaques are responsible for the buildup that clogs brain cells and eventually calls disruption of communication and cell death.
The Fluselenamyl bound to the plaques 2-10 times more efficiently than current imaging compounds used in Alzheimer’s tests. The compound was also able to identify the plaque buildups in brain samples of patients who died from Alzheimer’s.
Why did the researchers do perform this study?
The study found that drug trials to reverse Alzheimer’s symptoms have been ineffective because it seems doctors must start these treatments during the preclinical stage. To have effective treatments, doctors must be able to diagnose early.
Alzheimer’s Disease Progression Leads to Impairments of Your Ability to Work and Care for Yourself
Many think Alzheimer’s is a natural part of aging, but when it begins affecting your ability to work at a relatively young age, it might qualify you for Social Security disability benefits.
Call the Disability Help Group at 800-800-2009 to discuss your situation with our disability advocates.